Inhaled treprostinil significantly improves exercise capacity in terms of 6-minute walking distance (6MWD) over 16 weeks compared with placebo in patients with pulmonary hypertension associated with interstitial lung disease (ILD), according to the INCREASE trial presented at ATS 2020.
While gastroesophageal reflux disease is a common comorbidity in idiopathic pulmonary fibrosis (IPF), treatment with a proton pump inhibitor does not appear to have any bearing on mortality and hospitalization outcomes among IPF patients, according to real-world data.
Increased levels of serum high-mobility group box 1 (HMGB1) is associated with earlier onset of acute exacerbation (AE) in stable idiopathic pulmonary fibrosis (IPF) patients and shorter survival in those with AE-IPF, a recent study has shown. This signifies that HMGB1 predicts the acute deterioration of IPF.
Persistent or chronic viral infections, such as Epstein-Barr virus and cytomegalovirus, may promote the development, but not exacerbation, of idiopathic pulmonary fibrosis, according to the results of a meta-analysis.
Real-time exhaled breath analysis using secondary electrospray ionization-mass spectrometry has validated previous findings of elevated lung tissue amino acid levels in idiopathic pulmonary fibrosis (IPF), claims a new study, suggesting that online breath analysis can be a practical tool for rapid screening for IPF.
Patients with sporadic idiopathic pulmonary fibrosis (IPF) aged <60 years and who have nonspecific immunological or haematological abnormalities are at increased risk of telomere shortening, as well as present a poorer prognosis, according to a study.
INPULSIS-ON*, the open-label extension of the phase III INPULSIS trials, demonstrated the safety of nintedanib over a long-term period of treatment in patients with idiopathic pulmonary fibrosis (IPF).
There have been a substantial number of severe adverse events (SAE) and a faster decrease in forced vital capacity (FVC) in patients with possible idiopathic pulmonary fibrosis (posIPF) taking steroid therapy, a new study has shown.
Patients with combined pulmonary fibrosis and emphysema (CPFE) are likely to develop pulmonary hypertension, and this likelihood may be explained by the summed extents of interstitial lung disease (ILD) and emphysema, according to a study.